Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics is well positioned to capitalize on the potential of precision therapeutics, with their proprietary platform providing a deeper understanding of gene expression and potential drug targets. The company has a diverse pipeline, with FHD-909 in Phase 1 trials, and promising preclinical data for their combination treatments for AML. Leadership with strong experience and partnerships with experts in oncology further solidify the potential success of Foghorn's approach.

Bears say

Foghorn Therapeutics is a clinical stage biotechnology company that focuses on developing precision therapeutics for serious diseases through targeting the chromatin regulatory system. While they have a promising flagship program, FHD-909, there are significant development and competitive risks facing the company. Additionally, their partner, Eli Lilly, will play a crucial role in the success of FHD-909 and until data is disclosed, it is unclear if the partnership will move forward. Furthermore, their reliance on their proprietary platform and the need for high target coverage for optimal efficacy may pose challenges for future development.

Foghorn Therapeutics (FHTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.